ENYO Pharma SAS

Eli Lilly showed its confidence in Scorpion Therapeutics’ precision drug development efforts by agreeing in January to pay up to $2.5bn for the company to access its lead drug candidate, the PI3Kα i

In a sure sign that the annual J.P. Morgan Healthcare Conference in San Francisco will soon be under way, the waning days of December and the first week of January brought a deluge of new funding anno

The dominos fell as expected in the non-alcoholic steatohepatitis (NASH) R&D space as Intercept Pharmaceuticals, Inc. announced late on 22 June that it had received a second complete response letter

Organizers of a new European initiative to speed up the search for potential treatments for COVID-19 and future coronavirus threats have framed the project as an “unprecedented” exercise in cooperatio